CyGenics Ltd (ASX: CYN) today updated the market on its commercialisation plans and financial resources allocation across its four key businesses for 2006 after completing a strategy review with a detailed assessment of the resource allocations and priorities of each subsidiary business.
Friday 23 December 2005: Clinical Cell Culture Ltd (C3, ASX: CCE) Clinical Cell Culture (ASX: CCE) would like to clarify aspects of its application for approval to sell its ReCell tissue engineering device in Australia following media comments by the Therapeutic Goods Administration (TGA).
Life Therapeutics (ASX: LFE) announced today that all the Directors and number of Executives purchased 890,000 shares in the Company yesterday.
CyGenics Ltd. (ASX: CYN) today announced the appointment of Associate Professor Mark Kirkland as its Chief Scientific Officer, with effect from 1st December 2005.
Apollo Life Sciences (ASX: AOP) today announced that it has produced a new
range of protein detection kits for the scientific research market. These
kits incorporate proteins expressed exclusively from human cells.
Australian biopharmaceutical development company BioDiem Ltd (ASX: BDM) announced today it has received regulatory approval to commence a phase I/II clinical trial for its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.
Clinical Cell Culture Ltd (ASX: CCE) is pleased to announce the appointment of Helicon Group (Helicon), through their Chinese partner Cobra Bio Health Services International (Cobra), as the distributor of ReCell(R) in China.
